Genotropin

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis1
77Growth hormone secreting pituitary adenoma1
107Juvenile idiopathic arthritis3
IDDisease name (Link within this page)Number of trials
187Kabuki syndrome1
193Prader-Willi syndrome5

13. Multiple sclerosis


Clinical trials : 3,685Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

77. Growth hormone secreting pituitary adenoma


Clinical trials : 351Drugs : 241 - (DrugBank : 28) / Drug target genes : 26 - Drug target pathways : 87 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

107. Juvenile idiopathic arthritis


Clinical trials : 477Drugs : 232 - (DrugBank : 53) / Drug target genes : 66 - Drug target pathways : 160 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

187. Kabuki syndrome


Clinical trials : 4Drugs : 6 - (DrugBank : 2) / Drug target genes : 3 - Drug target pathways : 17 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

193. Prader-Willi syndrome


Clinical trials : 128Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries